Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 196

Results For "drug"

3018 News Found

MTPA announces long-term findings from post-marketing safety study of Radicava
News | June 30, 2022

MTPA announces long-term findings from post-marketing safety study of Radicava

Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone


Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine
News | June 30, 2022

Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses


Glenmark Pharmaceuticals expand its OTC portfolio
News | June 29, 2022

Glenmark Pharmaceuticals expand its OTC portfolio

The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world


Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Digitisation | June 28, 2022

Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv

Strengthens investment in channels of the future to expand patient reach


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
Drug Approval | June 27, 2022

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects


Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
News | June 27, 2022

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
Drug Approval | June 24, 2022

ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP

ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.


Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
People | June 24, 2022

Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D

Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.